Griseofulvin Suspension
NDC Package 62135-968-41

11-digit billing NDC: 62135096841 · Billing unit: ML · 120 ML per package

Package Information

Griseofulvin (griseofulvin (microsize)) suspension is major indications for Griseofulvin Oral Suspension, USP are:Tinea capitis (ringworm of the scalp) Tinea corporis (ringworm of the body) Tinea pedis (athlete's foot) Tinea unguium (onychomycosis; ringworm of the nails) Tinea cruris (ringworm of the thigh) Tinea barbae (barber’s itch) Griseofulvin Oral Suspension, USP inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: Trichophyton rubrumTrichophyton tonsuransTrichophyton mentagrophytesTrichophyton interdigitalisTrichophyton verrucosumTrichophyton sulphureumTrichophyton schoenleiniMicrosporum audouini Microsporum canisMicrosporum gypseumEpidermophyton floccosumTrichophyton megniniTrichophyton gallinae Trichophyton crateriformNote: Prior to therapy, the type of fungi responsible for the infection should be identified. This formulation utilizes a suspension delivery system. Marketed by Chartwell Rx, Llc., this product is identified by NDC 62135-968 and is authorized under FDA application ANDA065200.

Identification & Billing

NDC Package Code
62135-968-41
Package Description
120 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
62135096841
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
120 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Griseofulvin
Non-Proprietary Name
Griseofulvin (microsize)
Substance Name
Griseofulvin
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Major indications for Griseofulvin Oral Suspension, USP are:Tinea capitis (ringworm of the scalp) Tinea corporis (ringworm of the body) Tinea pedis (athlete's foot) Tinea unguium (onychomycosis; ringworm of the nails) Tinea cruris (ringworm of the thigh) Tinea barbae (barber’s itch) Griseofulvin Oral Suspension, USP inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: Trichophyton rubrumTrichophyton tonsuransTrichophyton mentagrophytesTrichophyton interdigitalisTrichophyton verrucosumTrichophyton sulphureumTrichophyton schoenleiniMicrosporum audouini Microsporum canisMicrosporum gypseumEpidermophyton floccosumTrichophyton megniniTrichophyton gallinae Trichophyton crateriformNote: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone. It is not effective in: Bacterial infections Candidiasis (Moniliasis) Histoplasmosis Actinomycosis Sporotrichosis Chromoblastomycosis Coccidioidomycosis North American Blastomycosis Cryptococcosis (Torulosis) Tinea versicolor Nocardiosis

Regulatory & Marketing

Labeler Name
Chartwell Rx, Llc.
Product Type
Human Prescription Drug
FDA Application #
ANDA065200
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-02-2005
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62135-968-41 identifies a specific commercial package of 120 ml in 1 bottle of Griseofulvin, a human prescription drug labeled by Chartwell Rx, Llc.. This suspension is formulated for oral use and contains griseofulvin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chartwell Rx, Llc. on March 02, 2005. The current certification is valid through December 31, 2027.

How is this Chartwell Rx, Llc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62135096841. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62135-968-41
11-Digit CMS (5-4-2)
62135-0968-41

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.